Bristol‑Myers Squibb Seen as Most Undervalued Large‑Cap Healthcare Stock in the S&P 500

Why It Matters

Bristol‑Myers Squibb’s undervaluation highlights a broader tension in large‑cap pharma: the balance between legacy drug erosion and the promise of next‑generation therapies. For portfolio managers, the stock offers a rare low‑multiple entry point into a sector where most peers trade at premium valuations, potentially enhancing risk‑adjusted returns. Moreover, the company’s aggressive cost‑reduction plan and robust pipeline could set a template for other large‑cap drugmakers grappling with patent cliffs, influencing sector‑wide valuation benchmarks. If BMY’s newer‑drug growth sustains and cost efficiencies materialize, the market may need to recalibrate its pricing models for large‑cap pharma, shifting the yardstick from legacy revenue stability to pipeline momentum and operational discipline. This could spur a re‑rating of other undervalued names and reshape capital allocation across the healthcare index.

Key Takeaways

• BMY trades at ~10× forward earnings and 9.9× trailing FCF, the cheapest among S&P 500 pharma peers.
• Q1 2026 revenue rose 3% YoY to $11.5 billion; growth portfolio up 12% to $6.2 billion.
• Newer drugs: Breyanzi +56%, Camzyos +97%, Reblozyl +16% YoY.
• Eliquis generated $4.14 billion in Q1, up 16% YoY; projected 10‑15% additional growth in 2026.
• Management targets $2 billion in annual cost savings by 2027.

Pulse Analysis

Bristol‑Myers Squibb’s current valuation reflects a classic market overreaction to patent‑cliff risk, a pattern seen in previous cycles when legacy drugs lose exclusivity. Historically, firms that successfully transition revenue to newer assets—such as Johnson & Johnson in the early 2010s—have seen their multiples rebound sharply. BMY’s 12% growth in its newer‑drug segment, now over half of total sales, suggests a similar trajectory may be underway. The $2 billion cost‑saving initiative, if realized, would lift operating margins and free cash flow, further narrowing the discount to peers.

From a macro perspective, the healthcare sector is benefitting from elevated dividend yields as investors chase yield in a low‑rate environment. BMY’s >4% yield, combined with its low multiple, positions it as a hybrid income‑growth play. However, the upside is contingent on the company’s ability to navigate regulatory approvals for pipeline candidates like iberdomide and mezigdomide. A miss on these catalysts could reignite concerns about revenue stagnation and re‑price the stock deeper into discount territory.

In the near term, the market will likely price in the upcoming Q2 earnings, where BMY is expected to report continued strength in Eliquis and its oncology franchise. A beat on revenue or margin guidance could trigger a rapid multiple expansion, while a miss could reinforce the current undervaluation narrative. Investors should monitor the timing of cost‑saving milestones and the outcomes of late‑stage trials, as these will be the decisive factors that determine whether BMY remains a value anomaly or reverts to a more typical large‑cap pharma valuation.